Pharma Industry

Platform allows for highly precise detection of disease-specific cell-free DNA

ARS Pharmaceuticals is offering two cartons of neffy nasal spray to schools, including ongoing replacement doses

The potential CMS model would set a $2 copayment for common generic drugs in an effort to improve medication adherence.

New prices would take effect in 2027.

Rep. Greg Murphy, MD (R-North Carolina), discusses reforms he hopes Congress will consider this year.

A Weill Cornell Medicine study found that one-third of all Medicare Part D pharmacy spending and nearly 40% of specialty drug spending within Medicare Part D was through pharmacies owned by the four largest PBMs: CVS, UnitedHealth Group, Cigna and Humana.

Sheila P. Burke, chair, Government Relations and Public Policy Group, Baker Donelson Law Firm, explains how the Trump administration might approach drug pricing policy.

New statement aims to ensure access to tirzepatide as other GLP-1 drug shortages persist.

CMS Office of the Actuary publishes annual price tag; physicians got $978 billion of it.

Health care organizations respond to ‘mixed bag’ bill.

ACP also calls for action on prior authorizations.

Ferguson, who opposed ban of noncompetes, named to succeed Chair Khan; new commissioner Meador called for PBM regulations.

PBMs are powerful middlemen that control prescription drug access for millions of Americans, and their business model is nefarious -- but currently legal.

The regulatory battle over compounded semaglutide and health effects on the heart are among latest developments involving GLP-1 RA drugs.

Robert Kushner, MD, an expert in overweight, obesity, nutrition, diet and exercise, discusses the effects of the new antiobesity medications.

The rate of pharmacy store closures has more than doubled in recent years in what researchers call an “unprecedented decline.”

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

Proposals would require more public data on prior authorization processes and whether those advance health equity.

Will it take effect? Biden proposal would be finalized in Trump’s term, and his pick to lead HHS has spoken against antiobesity drugs.

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

On behalf of Patients for Safer Nuclear Medicine, we object to the content of Cathy Sue Cutler’s column dismissing efforts to improve nuclear medicine safety and transparency.

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

As we prepare for a new Congress in January, it’s essential to ensure legislators and their staff fully understand the implications of nuclear medicine policy shifts on patient care and medical innovation.

Antitrust chief says the nation is at an inflection point to restore competition or pay more money for less choice and more aggravation.

At the Financial Times Global Pharma and Biotech Summit 2024, a panel discussed the potential of mRNA technology in developing cancer vaccines amid distrust from the public.